Clinical trial · Interventional
Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer
A Multicenter, Randomized Clinical Investigation of Trelstar Versus Continued Therapy in Patients Receiving Lupron or Zoladex for Advanced Prostate Cancer
NCT02749825CI-TRIAL-00021911terminatedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Withdrawal of funding support
Summary
Brief summary (as posted)
This research study looks at Testosterone levels in patients receiving Trelstar versus those receiving Lupron or Zoladex. These drugs have been approved for treatment of Prostate Cancer by the FDA.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lupron | Drug | Leuprolide | ALIAS |
| Trelstar | Drug | Triptorelin | ALIAS |
| Zoladex | Drug | Goserelin | ALIAS |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Trelstar
- description
- Per prescribing information
- interventionNames
- Drug: Trelstar
- type
- ACTIVE_COMPARATOR
- label
- Lupron
- description
- Per prescribing information
- interventionNames
- Drug: Lupron
- type
- ACTIVE_COMPARATOR
- label
- Zoladex
- description
- Per prescribing information
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced Prostate Cancer * Currently taking Lupron or Zoladex * Stable PSA * Baseline testosterone below castration level * Life expectancy \> 6 months * Eastern Cooperative Oncology Group performance status of 0-2 * Signed, approved informed consent. Exclusion Criteria: * Known hypersensitivity to any leuteinizing hormone releasing hormone (LHRH) agonist * Ongoing therapy with hyperprolactinemic agents * Antiandrogen therapy within 28 days prior to study start * Prior Orchiectomy, hypophysectomy or adrenalectomy * Chemotherapy, radiotherapy, or prostatectomy within 28 days prior to study start * Use of any investigational agent 3 months prior to enrollment * Use of systemic corticosteroids within 28 days or during study * Other malignancies within 2 yrs prior to study start, except curatively treated skin cancers * Severe kidney or liver failure, based on adequate lab values * Other medical conditions which would be likely to interfere with compliance or completion of study requirements
References
Publications (0)
Data not yet available
No reference posted for this study.